GW Pharmaceuticals PLC- (NASDAQ:GWPH) COO Christopher J. Tovey sold 1,200 shares of the business’s stock in a transaction on Wednesday, May 15th. The shares were sold at an average price of $15.01, for a total transaction of $18,012.00. Following the transaction, the chief operating officer now owns 3,703 shares in the company, valued at approximately $55,582.03. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
GWPH traded down $5.55 during trading on Friday, hitting $175.05. 410,018 shares of the company’s stock were exchanged, compared to its average volume of 470,429. The company has a current ratio of 7.81, a quick ratio of 7.19 and a debt-to-equity ratio of 0.03. GW Pharmaceuticals PLC- has a fifty-two week low of $90.14 and a fifty-two week high of $196.00. The company has a market cap of $5.28 billion, a price-to-earnings ratio of -16.58 and a beta of 2.75.
GW Pharmaceuticals PLC- (NASDAQ:GWPH) last released its quarterly earnings data on Monday, May 6th. The biopharmaceutical company reported ($1.68) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.48) by $0.80. GW Pharmaceuticals PLC- had a negative net margin of 458.79% and a negative return on equity of 45.75%. The firm had revenue of $39.20 million for the quarter, compared to the consensus estimate of $12.32 million. During the same quarter in the prior year, the company posted ($3.12) earnings per share. The business’s revenue was up 1189.5% on a year-over-year basis. As a group, equities analysts forecast that GW Pharmaceuticals PLC- will post -4.55 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Horan Capital Advisors LLC. acquired a new position in GW Pharmaceuticals PLC- during the first quarter worth $25,000. Exane Derivatives acquired a new position in GW Pharmaceuticals PLC- during the first quarter worth $28,000. TCG Advisors LP acquired a new position in GW Pharmaceuticals PLC- during the first quarter worth $29,000. Mckinley Capital Management LLC Delaware acquired a new position in GW Pharmaceuticals PLC- during the fourth quarter worth $30,000. Finally, Institutional & Family Asset Management LLC acquired a new position in GW Pharmaceuticals PLC- during the first quarter worth $31,000. Hedge funds and other institutional investors own 79.60% of the company’s stock.
GWPH has been the topic of a number of research reports. BidaskClub downgraded shares of GW Pharmaceuticals PLC- from a “buy” rating to a “hold” rating in a research report on Thursday, February 21st. Morgan Stanley reiterated a “buy” rating on shares of GW Pharmaceuticals PLC- in a research report on Tuesday, April 9th. Piper Jaffray Companies reiterated an “overweight” rating and set a $185.00 target price on shares of GW Pharmaceuticals PLC- in a research report on Wednesday, February 27th. Zacks Investment Research upgraded shares of GW Pharmaceuticals PLC- from a “hold” rating to a “buy” rating and set a $165.00 target price on the stock in a research report on Wednesday, February 6th. Finally, Oppenheimer downgraded shares of GW Pharmaceuticals PLC- from an “outperform” rating to a “market perform” rating and set a $195.00 target price on the stock. in a research report on Wednesday, May 8th. One equities research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $205.40.
TRADEMARK VIOLATION WARNING: “Christopher J. Tovey Sells 1,200 Shares of GW Pharmaceuticals PLC- (GWPH) Stock” was reported by Transcript Daily and is the property of of Transcript Daily. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://transcriptdaily.com/2019/05/19/christopher-j-tovey-sells-1200-shares-of-gw-pharmaceuticals-plc-gwph-stock.html.
About GW Pharmaceuticals PLC-
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.
Recommended Story: Market Capitalization
Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.